

SRC-1 Blocking Peptide



Orders ■ 877-616-CELL (2355)
orders@cellsignal.com

Support ■ 877-678-TECH (8324)
info@cellsignal.com

Web ■ www.cellsignal.com

rev. 06/02/17

For Research Use Only. Not For Use In Diagnostic Procedures.

Description: This peptide is used to block SRC-1 (128E7) Rabbit mAb #2191 reactivity in peptide dot blot protocols.

Background: There are three members of the steroid receptor co-activator (SRC) family of proteins: SRC-1 (NCoA-1), SRC-2 (TIF2/GRIP1/NCoA-2), and SRC-3 (ACTR/pCIP/RAC3/TRAM-1/AIB1). All SRC family members share significant structural homology and function to stimulate transcription mediated by nuclear hormone receptors and other transcriptional activators such as Stat3, NF- κ B, E2F1, and p53 (1-4). Two SRC proteins, SRC-1 and SRC-3, function as histone acetyltransferases (5,6). In addition, all three family members can recruit other histone acetyltransferases (CBP/p300, PCAF) and histone methyltransferases (PRMT1, CARM1) to target promoters and cooperate to enhance expression of many genes (5-8). The SRC proteins play important roles in multiple physiological processes including cell proliferation, cell survival, somatic cell growth, mammary gland development, female reproductive function, and vasoprotection (9). SRC-1 and SRC-3 are conduits for kinase-mediated growth factor signaling to the estrogen receptor and other transcriptional activators. Seven SRC-1 phosphorylation sites and six SRC-3 phosphorylation sites have been identified, which are induced by steroids, cytokines, and growth factors and involve multiple kinase signaling pathways (9-11). Research has shown that all three SRC family members are associated with increased activity of nuclear receptors in breast, prostate, and ovarian carcinomas. According to the literature, SRC-3 is frequently amplified or overexpressed in a number of cancers (12), and SRC-1/PAX3 and SRC-2/MYST3 translocations are found associated with rhabdomyosarcoma and acute myeloid leukemia, respectively (13,14).

Quality Control: The quality of the peptide was evaluated by reversed-phase HPLC and by mass spectrometry. The peptide blocks SRC-1 (128E7) Rabbit mAb #2191 by peptide dot blot.

Directions for Use: Use as a blocking reagent to evaluate the specificity of antibody reactivity in peptide dot blot protocols. Recommended antibody dilutions can be found on the relevant product data sheet.

Entrez-Gene ID #8648

Swiss-Prot Acc. #Q15788

Storage: Supplied in 20 mM potassium phosphate (pH 7.0), 50 mM NaCl, 0.1 mM EDTA, 1 mg/ml BSA and 5% glycerol. 1% DMSO Store at -20°C.

Background References:

- (1) Giraud, S. et al. (2002) *J. Biol. Chem.* 277, 8004-8011.
- (2) Na, S.Y. et al. (1998) *J. Biol. Chem.* 273, 10831-10834.
- (3) Louie, M.C. et al. (2004) *Mol. Cell Biol.* 24, 5157-5171.
- (4) Lee, S.K. et al. (1999) *Mol. Endocrinol.* 13, 1924-1933.
- (5) Spencer, T.E. et al. (1997) *Nature* 389, 194-198.
- (6) Chen, H. et al. (1997) *Cell* 90, 569-580.
- (7) Koh, S.S. et al. (2001) *J. Biol. Chem.* 276, 1089-1098.
- (8) Chen, D. et al. (1999) *Science* 284, 2174-2177.
- (9) Wu, R.C. et al. (2004) *Mol. Cell* 15, 937-949.
- (10) Rowan, B.G. et al. (2000) *J. Biol. Chem.* 275, 4475-4483.
- (11) Zhou, H.J. et al. (2005) *Cancer Res.* 65, 7976-7983.
- (12) Torres-Arzuayus, M.I. et al. (2004) *Cancer Cell* 6, 263-274.
- (13) Wachtel, M. et al. (2004) *Cancer Res.* 64, 5539-5545.
- (14) Deguchi, K. et al. (2003) *Cancer Cell* 3, 259-271.